Showing results (1531-1540 of 1,915) with videos related to
Sort By:
Pageof 192
Current Neuropharmacology|November 26, 2021
Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective AgentsFlávia P Dias Viegas, Vanessa Silva Gontijo, Matheus de Freitas Silva, et al.Current Neuropharmacology|December 2, 2021
Biological Mechanism-based Neurology and Psychiatry: A BACE1/2 and Downstream Pathway ModelHarald Hampel, Giuseppe Caruso, Robert Nisticò, et al.Current Neuropharmacology|December 2, 2021
Microtubule-modulating Agents in the Fight Against Neurodegeneration: Will it ever Work?Ahmed Soliman, Lidia Bakota, Roland BrandtCurrent Neuropharmacology|February 16, 2021
Gut Microbiota Regulate Astrocytic Functions in the Brain: Possible Therapeutic ConsequencesYa-Fei Zhao, Da-Neng Wei, Yong TangCurrent Neuropharmacology|February 8, 2021
Acid-Sensing Ion Channels: Focus on Physiological and Some Pathological Roles in the BrainMaksim Storozhuk, Andrii Cherninskyi, Oleksandr Maximyuk, et al.Current Neuropharmacology|February 26, 2021
Interaction between Zinc, GPR39, BDNF and Neuropeptides in DepressionKatarzyna MlyniecCurrent Neuropharmacology|February 26, 2021
Serine Proteases and Chemokines in Neurotrauma: New Targets for Immune Modulating Therapeutics in Spinal Cord InjuryRoxana N Beladi, Kyle S Varkoly, Lauren Schutz, et al.Current Neuropharmacology|February 11, 2017
YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's DiseasePaweł Muszyński, Magdalena Groblewska, Agnieszka Kulczyńska-Przybik, et al.Current Neuropharmacology|December 9, 2016
From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple SclerosisLilian Aly, Bernhard Hemmer, Thomas KornCurrent Neuropharmacology|October 6, 2022
Therapeutic Approaches to Non-Motor Symptoms of Parkinson's Disease: A Current Update on Preclinical EvidencePoornima D E Weerasinghe-Mudiyanselage, Sohi Kang, Joong-Sun Kim, et al.Pageof 192